When The Australian Financial Review caught up with Regal Partners’ star portfolio manager Jackson Aldridge in June, his Australian Small Companies Fund had returned nearly 40 per cent over the prior 12 months and was among the best in the country.
His long list of winners included ASX-listed medical software darling Artrya, which was developing an artificial intelligence-powered platform to improve the detection of coronary artery disease. Regal first bought the stock at 70¢ a share and watched it hit a record $6.49 by July this year. Aldridge was so bullish that he even slapped an internal price target of $50 on the stock.
Gift articles to anyone you choose each month when you subscribe.
